Muramyl dipeptide enhances the response to endotoxin to cause multiple organ injury in the anesthetized rat

Oliver Murch1, Maha Abdelrahman, Amar Kapoor

  • 1Centre for Experimental Medicine, Nephrology & Critical Care, The William Harvey Research Institute, St. Bartholomew's and The Royal London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, London, United Kingdom.

Shock (Augusta, Ga.)
|August 19, 2007
PubMed

Insights

Muramyl dipeptide (MDP) and lipopolysaccharide (LPS) bacterial components synergize to worsen organ injury and inflammation. This study shows MDP exacerbates LPS-induced systemic inflammation and organ damage in rats.

Area of Science:

  • Immunology
  • Microbiology
  • Pathology

Background:

  • Nucleotide oligomerization domain (NOD) proteins, like NOD2, detect bacterial peptidoglycan fragments.
  • NOD2 activation by muramyl dipeptide (MDP) amplifies inflammatory responses, particularly those induced by lipopolysaccharide (LPS).

Purpose of the Study:

  • To investigate how MDP affects organ injury and dysfunction when co-administered with a low dose of LPS.
  • To determine if MDP administration prior to LPS influences the severity of LPS-induced organ damage and inflammation.

Main Methods:

  • Male Wistar rats received co-administration or sequential administration of MDP and LPS.
  • Mean arterial pressure, heart rate, organ injury markers, plasma cytokine levels, and lung myeloperoxidase activity were measured.
  • Different dosages and timings of MDP and LPS administration were employed.

Main Results:

  • Coadministration of MDP (10 mg/kg) with LPS significantly increased organ injury, cytokine release, and lung injury compared to LPS alone.
  • Administering MDP (10 mg/kg) 24 hours before LPS also led to significantly enhanced organ injury and inflammation.
  • MDP potentiated the inflammatory and organ-damaging effects of LPS.

Conclusions:

  • The bacterial components MDP and LPS act synergistically to induce multiple organ injury and systemic inflammation.
  • These findings highlight the combined impact of NOD ligands and endotoxins in inflammatory conditions.
  • Further research into NOD ligands in inflammation models is warranted.

Related Concept Videos